

Radiation Oncology Coverage

Breast

- DCIS
- Invasive



Gynecologic

- Cervical
- Endometrial
- Vaginal
- Vulvar



Thoracic

- NSCLC
- SCLC



Genitourinary

- Bladder
- Prostate
- Seminoma



Head & Neck

- Hypopharynx
- Larynx
- Nasopharyngeal
- Oral Cavity
- Oropharynx
- Salivary Gland
- Paranasal Sinuses



Gastrointestinal

- Anal
- Gastric
 - Cardia
 - Non-cardia
- Esophageal
 - GE Junction
 - Non-GE Junction
- Pancreatic
- Rectal
- Liver
 - Clinical trials only



Skin

- Melanoma
- Squamous Cell
- Basal Cell
- Merkel Cell
- Kaposi's Sarcoma
- Keratoacanthoma



Bone

- Bone Metastasis
- Sarcoma



CNS

- Brain
 - Brainstem Glioma
 - Oligodendrogliomas
 - Cerebral Glioma
 - Astrocytoma
- Brain Metastasis



Hematologic

- Multiple Myeloma & Plasmacytoma
- Lymphomas:
 - Hodgkin's
 - Classic
 - Lymphocyte Predominant
 - Non-Hodgkin's
 - Low Grade, Follicular
 - Low Grade, Marginal Zone (MALT)
 - Diffuse Large B Cell



Endocrine

- Thyroid



Other

- Non-Neoplastic



Radiation Oncology: On Pathway Rates

*Data for all customers
(excluding Private Label centers)
Radiation Oncology
12 months ended 11/30/16*

Disease	On-Pathway Rate
Anal Carcinoma	80.6%
Benign Disease	100.0%
Bladder	84.7%
Bone Metastasis	96.9%
Brain	90.1%
Brain Metastasis	98.0%
Breast	96.0%
Cervical	88.3%
Endometrial	89.3%
Esophageal	97.5%
Gastric	84.6%
Head and Neck	94.6%
Hodgkin Lymphoma	73.0%
Mult. Myeloma & Plasmacytoma	94.9%
Non-Hodgkin Lymphoma	87.5%
Non-Small Cell Lung	83.5%
Ovarian	92.9%
Pancreatic	88.5%
Prostate	96.6%
Rectal	85.0%
Sarcoma	88.3%
Seminoma	88.9%
Skin	76.7%
Small Cell Lung	85.4%
Thyroid	86.5%
Vaginal	78.9%
Vulvar	82.7%
RadOnc Total	92.7%